These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

694 related articles for article (PubMed ID: 29723601)

  • 61. Metastatic-prone telomerase reverse transcriptase (TERT) promoter and v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutated tall cell variant of papillary thyroid carcinoma arising in ectopic thyroid tissue: A case report.
    Stenman A; Koman A; Ihre-Lundgren C; Juhlin CC
    Medicine (Baltimore); 2021 Jan; 100(2):e24237. PubMed ID: 33466206
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The histologic outcomes of indeterminate thyroid nodules with rat sarcoma mutations: A case series.
    Jones M; Abendano DG; Turner M; Sullivan C; Reyes MCD
    Diagn Cytopathol; 2023 Dec; 51(12):E332-E337. PubMed ID: 37583345
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cytological, molecular, and clinical features of noninvasive follicular thyroid neoplasm with papillary-like nuclear features versus invasive forms of follicular variant of papillary thyroid carcinoma.
    Zhao L; Dias-Santagata D; Sadow PM; Faquin WC
    Cancer Cytopathol; 2017 May; 125(5):323-331. PubMed ID: 28192645
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions.
    Ballester LY; Sarabia SF; Sayeed H; Patel N; Baalwa J; Athanassaki I; Hernandez JA; Fang E; Quintanilla NM; Roy A; López-Terrada DH
    Pediatr Dev Pathol; 2016; 19(2):94-100. PubMed ID: 26366474
    [TBL] [Abstract][Full Text] [Related]  

  • 65. BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization.
    Ciampi R; Zhu Z; Nikiforov YE
    Endocr Pathol; 2005; 16(2):99-105. PubMed ID: 16199894
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
    Pu RT; Yang J; Wasserman PG; Bhuiya T; Griffith KA; Michael CW
    Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is rare, benign lesion using modified stringent diagnostic criteria: Reclassification and outcome study.
    Cubero Rego D; Lee H; Boguniewicz A; Jennings TA
    Ann Diagn Pathol; 2020 Feb; 44():151439. PubMed ID: 31865250
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clear Cell Variant of a Follicular Thyroid Tumor With Uncertain Malignant Potential: A Case Report.
    Juhlin CC; Bränström R; Shabo I; Höög A
    Int J Surg Pathol; 2019 May; 27(3):290-293. PubMed ID: 30370813
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations.
    Cavaco BM; Batista PF; Martins C; Banito A; do Rosário F; Limbert E; Sobrinho LG; Leite V
    Endocr Relat Cancer; 2008 Mar; 15(1):207-15. PubMed ID: 18310288
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Trisomy 17 as a marker for a subset of noninvasive thyroid nodules with focal features of papillary carcinoma: cytogenetic and molecular analysis of 62 cases and correlation with histological findings.
    Frau DV; Lai ML; Caria P; Dettori T; Coni P; Faa G; Morandi L; Tallini G; Vanni R
    J Clin Endocrinol Metab; 2008 Jan; 93(1):177-81. PubMed ID: 17956956
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis.
    Vuong HG; Altibi AM; Duong UN; Ngo HT; Pham TQ; Tran HM; Oishi N; Mochizuki K; Nakazawa T; Hassell L; Katoh R; Kondo T
    Tumour Biol; 2017 Oct; 39(10):1010428317713913. PubMed ID: 29037127
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
    Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
    JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Mutational status may supersede tumor size in predicting the presence of aggressive pathologic features in well differentiated thyroid cancer.
    Semsar-Kazerooni K; Morand GB; Payne AE; da Silva SD; Forest VI; Hier MP; Pusztaszeri MP; Tamilia M; Payne RJ
    J Otolaryngol Head Neck Surg; 2022 Mar; 51(1):9. PubMed ID: 35246262
    [TBL] [Abstract][Full Text] [Related]  

  • 74. RAS-Mutant Follicular Thyroid Tumors: A Continuous Challenge for Pathologists.
    Hernandez-Prera JC; Wenig BM
    Endocr Pathol; 2024 Sep; 35(3):167-184. PubMed ID: 38888731
    [TBL] [Abstract][Full Text] [Related]  

  • 75. High Prevalence of DICER1 Mutations and Low Frequency of Gene Fusions in Pediatric Follicular-Patterned Tumors of the Thyroid.
    Bae JS; Jung SH; Hirokawa M; Bychkov A; Miyauchi A; Lee S; Chung YJ; Jung CK
    Endocr Pathol; 2021 Sep; 32(3):336-346. PubMed ID: 34313965
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
    Landa I; Ibrahimpasic T; Boucai L; Sinha R; Knauf JA; Shah RH; Dogan S; Ricarte-Filho JC; Krishnamoorthy GP; Xu B; Schultz N; Berger MF; Sander C; Taylor BS; Ghossein R; Ganly I; Fagin JA
    J Clin Invest; 2016 Mar; 126(3):1052-66. PubMed ID: 26878173
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Characterization of Activating Mutations of the
    Borrelli N; Panebianco F; Condello V; Barletta JA; Kaya C; Yip L; Nikiforova MN; Nikiforov YE
    Thyroid; 2019 Sep; 29(9):1279-1285. PubMed ID: 31407636
    [No Abstract]   [Full Text] [Related]  

  • 78. Follicular Thyroid Neoplasms: Comparison of Clinicopathologic and Molecular Features of Atypical Adenomas and Follicular Thyroid Carcinomas.
    Cracolici V; Ritterhouse LL; Segal JP; Puranik R; Wanjari P; Kadri S; Parilla M; Cipriani NA
    Am J Surg Pathol; 2020 Jul; 44(7):881-892. PubMed ID: 32282345
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma.
    Kim TY; Kim WB; Song JY; Rhee YS; Gong G; Cho YM; Kim SY; Kim SC; Hong SJ; Shong YK
    Clin Endocrinol (Oxf); 2005 Nov; 63(5):588-93. PubMed ID: 16268813
    [TBL] [Abstract][Full Text] [Related]  

  • 80. BRAF status of follicular variant of papillary thyroid carcinoma and its relationship to its clinical and cytological features.
    Proietti A; Giannini R; Ugolini C; Miccoli M; Fontanini G; Di Coscio G; Romani R; Berti P; Miccoli P; Basolo F
    Thyroid; 2010 Nov; 20(11):1263-70. PubMed ID: 20950194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.